Long non-coding RNAs in gastric cancer: New emerging biological functions and therapeutic implications

Huidan Tan1#, Shouyue Zhang1#, Jin Zhang1#, Lingjuan Zhu1,2#, Yanmei Chen1,2,3, Hongmei Yang4, Yi Chen1*, Yang An3*, Bo Liu1*

1State Key Laboratory of Biotherapy and Cancer Center, Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China
2College of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110064, China
3Department of Plastic Surgery, Peking University Third Hospital, Beijing 100191, China
4College of Stomatology, West China Hospital, Sichuan University, Chengdu 610041, China

#These authors contributed equally to this work.

*Corresponding authors: Prof. Yi Chen, MD., phone number: +86-28-85164063; E-mail: toddychan@163.com; Prof. Yang An, MD., phone number: +86-13264498382; E-mail: anyangdoctor@163.com; Prof. Bo Liu, Ph.D., phone number: +86-15708469925; E-mail: liubo2400@163.com.
Abstract

Gastric cancer (GC) is currently the fourth most common malignancy and the third leading cause of cancer-related deaths worldwide. Long non-coding RNAs (IncRNAs), transcriptional products with more than 200 nucleotides, are not as well-characterized as protein-coding RNAs. Accumulating evidence has recently revealed that maladjustments of diverse IncRNAs may play key roles in multiple genetic and epigenetic phenomena in GC, affecting all aspects of cellular homeostasis, such as proliferation, migration, and stemness. However, the full extent of their functionality remains to be clarified. Considering the lack of viable biomarkers and therapeutic targets, future research should be focused on unravelling the intricate relationships between IncRNAs and GC that can be translated from bench to clinic. Here, we summarized the state-of-the-art advances in IncRNAs and their biological functions in GC, and we further discuss their potential diagnostic and therapeutic roles. We aim to shed light on the interrelationships between IncRNAs and GC with respect to their potential therapeutic applications. With better understanding of these relationships, the biological functions of IncRNAs in GC development will be exploitable, and promising new strategies developed for the prevention and treatment of GC.

Keywords: Long non-coding RNA (IncRNA), Gastric cancer (GC), Biological function, Biomarker, Therapeutic application
Background

Gastric cancer (GC), one of the most common malignant tumors, is the second leading cause of cancer-related deaths worldwide after lung cancer and is a major cause of cancer-related mortality in China [1]. GC is classified anatomically into gastric adenocarcinoma and gastro-esophageal borderline adenocarcinoma. Histologically, it can be divided into two types: diffuse and intestinal [2,3]. With the present surgical techniques and the implementation of traditional radiotherapy, chemotherapy, and neoadjuvant therapy, 5-year overall survival of patients with early GC can reach 95%. However, GC is seldom diagnosed early and therefore in most patients the disease has progressed to an advanced stage by the time of clinical manifestation. As a result of the malignant invasion and metastasis that is seen in later stages, the traditional treatments of surgery and chemoradiotherapy are not as effective as in early disease, and the 5-year survival rate is <20% [4]. Currently, the main treatment for advanced GC (AGC) includes combinations of chemoradiotherapy, molecular targeted therapy, and immunotherapy. In order to better understand the pathogenesis of GC and identify more effective biomarkers predicting prognosis and response to treatment, extensive research is needed on all aspects of the disease. Recently, compelling evidence has emerged for an important role
of long non-coding RNAs (IncRNAs) in the pathogenesis and progression of GC through intricate molecular signaling networks.

The human genome contains a vast array of nucleotides, and these complex sequences can be transcribed and finally translated into more than 100,000 proteins. Of these, only 2% constitute transcripts that encode mature proteins; the remaining 98%, called non-coding RNAs (ncRNAs), do not encode proteins but still play essential roles in cell biology [5]. NcRNAs with more than 200 nucleotides are classified as IncRNAs; these account for more than 80% of ncRNAs, and are the new focus points in cancer research. Many IncRNAs have conserved secondary structures, shear forms, and subcellular localization; their conservation and specificity suggest that they are functional. However, their functions are more difficult to determine than those of microRNAs and proteins, because they cannot be inferred from their sequences or structures alone [6]. Based on their locations in the genome relative to the protein-coding genes, IncRNAs can be divided into five types: sense, antisense, bidirectional, intronic, and intergenic. Compared with the transcriptional orientation of the coding RNAs, the transcriptional orientation of IncRNAs can be antisense in addition to sense. Antisense IncRNAs transcripts are initiated inside or 3' of protein-coding genes, transcribed in the opposite direction to the protein-coding genes, and overlap by at least one exon. Bidirectional IncRNAs are initiated in different ways from the promoter of a protein-coding gene; the distance that constitutes bidirectionality is usually within hundreds of base pairs. Intron IncRNAs are initiated within introns of protein-coding genes and overlap entirely with these introns. Finally, intergenic IncRNAs are defined with different transcription units from protein-coding genes [7]. From another point of view, IncRNAs can be divided into nuclear IncRNAs and cytoplasmic IncRNAs, and this classification according to subcellular localization plays a key role in predicting their function. Most nuclear IncRNAs are involved in the regulation of epigenetic events and transcription, while IncRNAs in the cytoplasm play a major role at the post-transcriptional level. Thus, knowledge of such positional relationships is useful to infer the functions of IncRNAs. In addition, the promoter upstream transcripts (PROMPTs) and enhancer-associated RNAs (eRNAs)
transcribed from promoters and enhancers, respectively, are similar to regulatory DNA elements in terms of their functional mechanisms [6]. Unlike other IncRNAs, PROMPTs share some regulatory elements with the promoters of adjacent protein-coding genes. The expression and function of PROMPTs is often associated with adjacent protein encoding transcripts. In mammals, PROMPTs are transcribed in the antisense orientation, about 0.5–2.5 kb from the transcription start sites (TSSs) of the protein-coding gene [8].

eRNAs are a group of IncRNAs transcribed from enhancers, which can promote enhancer function, and their regulation of gene expression is an emerging research field. eRNAs can recruit transcription factors, transcriptional co-activators, and chromatin remodelers in either cis or trans to regulate gene transcription and hence biological processes. Unlike common IncRNAs, eRNAs have similar transcription rates but produce fewer stable transcripts [9]. In addition, IncRNAs possess certain characteristics similar to those of mRNAs; for instance, IncRNAs are transcribed by RNA polymerase II, they contain a promoter, and their structure consists of multiple exons, equipped with 5’ caps and 3’ poly A tails that are spliced into mature transcripts by a typical mechanism [10]. Similar to the protein-coding genes, their genomic positions are marked by Histone H3 lysine K4 (H3K4) trimethylation at the transcription initiation site and H3K36 trimethylation enrichment throughout the genome; however, compared to the protein-coding transcripts, there are fewer exons in IncRNAs and the overall level of expression is lower [11].

Despite being initially regarded as “transcriptional noise,” accumulating evidence indicates that IncRNAs influence local or global gene expression via transcriptional, post-transcriptional, and epigenetic regulatory mechanisms [12]. Over the past decade, significant progress has been made in the study of GC-related IncRNAs, which are involved in a variety of tumor signaling pathways, such as Notch, mTOR, NF-κ B, and Wnt [13].

With the advent of high-throughput sequencing technology, novel IncRNAs, considered an important class of RNA, are being intensely investigated. Some IncRNAs have been found to have functional roles in the pathogenesis and development of cancer, and could be potential therapeutic targets or biomarkers for diagnosis and prognosis.
Thus, these new findings will provide an insight into more new strategies for the diagnosis and treatment of IncRNAs in gastric cancer.

Multi-functional roles of IncRNAs in gastric cancer

LncRNAs are involved in many epigenetic mechanisms, including histone modification, DNA methylation, hydroxymethylation, and chromatin remodeling, which control the expression of regulatory factors involved in the progression of GC, such as genes related to DNA repair, apoptosis, autophagy, and regulators of cell cycle, transcription, and signaling pathways [14]. In addition, IncRNAs can hybridize with pre-mRNAs to modulate their alternative splicing by blocking the recognition of splice sites by spliceosomes to produce alternative transcripts [15]. LncRNAs located in the cytoplasm most commonly act as molecular sponges of miRNAs, thereby regulating the expression of the downstream miRNAs [16]. Moreover, IncRNAs can bind directly to proteins, affecting protein activity, localization, and protein–protein interactions [17]. Therefore, here we specifically describe three levels of molecular mechanisms of IncRNAs in the progression of GC, namely at the DNA, RNA, and protein levels (Figure 1 and Table 1).
Figure 1. Multi-functional roles of IncRNAs in gastric cancer. In the nucleus, IncRNAs can participate in a variety of epigenetic mechanisms by recruiting chromatin modifiers, including (a) histone modifications, (b) DNA methylations, (c) chromatin remodeling; in addition, IncRNAs can participate in (d) splicing modulations of mRNAs. In the cytoplasm, IncRNAs can interact with RNAs, which can not only (e) regulate translation of mRNAs, but also act as (f) miRNA sponges to alleviate miRNAs' inhibition of target genes. In addition, IncRNAs can directly (g) interact with proteins, affecting protein activity, localization, or as structural components.

LncRNAs and epigenetic modifications

Histone modifications

Epigenetic modifiers are by far the most common protein partners of IncRNAs, and considerable attention has been lavished on their members, including histone methyltransferase and Polycomb Repressive Complex (PRC2) [18]. PRC2, a methyltransferase composed of EZH2, SUZ12, and EED, epigenetically regulates gene expression by catalyzing the methylation and trimethylation of lysine residue 27 of
histone 3 (H3K27me3) [19]. About 20% of human lncRNAs are reported to associate physically with PRC2, suggesting that they may play a general role in recruiting PRC2 to its target genes [20]. Other epigenetic modifiers including LSD1, SMYD3, WDR5, SET1C, KMT2C, ING2, and PAQR3 may also be potential partners for lncRNAs [21-23]. One of the many lncRNAs acting on epigenetic modifiers is urothelial cancer-associated 1 (UCA1). RNA sequencing (RNA-seq) analysis showed that UCA1 knockout preferentially affects genes related to the cell cycle, proliferation, and migration. UCA1 promotes cell proliferation by binding to the histone methyltransferase EZH2 to inhibit the expression of Sprouty RTK signaling antagonist 1 (SPRY1) and P21, a cyclin-dependent kinase (CDK) inhibitor [24]. SPRY1, part of the mammalian sprouty gene family consisting of four members (SPRY1–4), has tumor suppressive activity and is downregulated in certain tumors such as prostate and breast cancer [25,26]. UCA1 was found to mediate the trimethylation of H3K27 in P21 and SPRY1 promoters [24]. Therefore, it can be concluded that UCA1, via its action on EZH2, can also influence GC progression, at least partially, through the epigenetic inhibition of P21 and SPRY1.

As an important member of the TEA domain (TEAD) family, TEAD4 is considered to be a key transcription factor involved in the development of various cancers including GC [27,28]. By binding to MNX1-AS1 (MNX1 antisense RNA 1) promoter, TEAD4 facilitates the transcription of MNX1-AS1, and acts as a carcinogen at the level of transcription. MNX1-AS1 can also act on EZH2 by recruiting EZH2 and H3K27me3 to the BTG2 (B-cell translocation gene 2) promoter and thus partially inhibiting BTG2, a tumor suppressor, thereby contributing to carcinogenicity in GC [29].

The expression of Small Nucleolar RNA Host Gene 3 (SNHG3) is elevated in GC, and high SNHG3 is associated with poor prognosis [30]. Because it is well-established that the mode of action of IncRNAs is by regulating adjacent genes, the relative expression of the MED18 (mediator subunit 18) gene adjacent to SNHG3 was analyzed [31]. MED18, a component of the Mediator complex and coactivator of DNA-binding factors that activate transcription by RNA polymerase II, is involved in regulation of lipid and peroxisome metabolism. SNHG3 knockdown weakened the enrichment of EZH2 in
the MED18 promoter, which led to a decrease in methylation level and the upregulation of the MED18 promoter [30].

RNA immunoprecipitation (RIP) experiments showed that the IncRNA ARHGAP27P1 specifically bound only to the chromatin modifier Jumonji domain-containing 3 (JMJD3). Over-expression of ARHGAP27P1 enhanced the association between ARHGAP27P1 and JMJD3, resulting in a significant decrease in H3K27me3, thus eventually facilitating the transcription of P15, P16, and P57. Furthermore, the inhibitory effect of ARHGAP27P1 on cell proliferation and cell cycle progression can be reversed by knocking down JMJD3, P15, or P16 [32].

Studies have also revealed an involvement of some IncRNAs in GC through their action as modular scaffolds of WDR5 and KAT2A complexes, such as GCLNC1 and GCAWKFR; some IncRNAs such as LINC00673 and FEZF1-AS1 act directly on LSD1, and thus regulate the expression of their downstream targets [21,33-35].

**DNA methylations**

DNA methylation is one of the most stable and common chromatin modifications associated with gene inactivation. Small nucleolar RNA host gene 1 (SNHG1) induces GC development in a DNMT1-dependent manner; DNMT1 is the most abundant DNA methyltransferase in mammalian cells. In tissues with EBV-positivity, microsatellite instability, and chromosomal instability, the expression of SNHG1 was significantly higher than in tissues that are genomic stable. Thus, SNHG1 can regulate the expression of DNMT1 at both the RNA and protein levels, so it plays a key role in GC by affecting epigenetic regulation [36].

Increased IncRNA-AK058003 expression is frequently found in hypoxic GC. This regulates the expression of γ-synuclein (SNCG), a tumor metastasis-related gene involved in hypoxia-induced GC metastasis. AK058003 promotes hypoxia-induced GC metastasis and invasion by activating SNCG via the initiation of DNA demethylation of its CPG islands [37].

Studies on MEG3 in diabetic patients indicated that potential DNA methylation in the
promoter region resulted in the reduction of target gene expression, thereby affecting
disease development [38]. This was also observed in GC, where MEG3 levels are
significantly lower and its methylation significantly greater in tumor cells than in
para-cancerous tissues, as demonstrated in multiple GC cell lines [39]. Furthermore,
DNA methylation affects the expression of MEG3 and its target miR-29 in HCC [40].
Similarly in GC, DNA methylation affects the expression of the MEG3 target miR-181a-5p,
a tumor suppressor, thus downregulating the downstream target ATG4B
(autophagy-associated 4B) [39].

**LncRNAs act at the post-transcriptional level**

**mRNA translation**

Some lncRNAs affect RNA translation by binding and stabilizing mRNAs. Recently,
MACC1-AS1 (MACC1 antisense RNA 1), which is elevated under metabolic stress, was
shown to promote the stability of MACC1 (metastasis-associated in colon cancer-1)
mRNA by physically binding to it, as well as increasing its expression [41]. MACC1, a key
regulator of the HGF/c-MET axis, is an important target for tumor therapy [42]. In addition,
MACC1-AS1 has been shown to enhance metabolic plasticity by upregulating MACC1
and subsequently enhancing glycolysis and antioxidant capacity, possibly through the
AMPK/Lin28 pathway [41]. AMPK and Lin28 are both important RNA-binding proteins
(RBPs) that regulate the stability of mRNA.

Ephrin A1, which is either upregulated or downregulated in different cancers, is
associated with tumor progression, malignancy, and prognosis [43]. GC cells exhibit high
amounts of GMAN (gastric cancer metastasis associated long noncoding RNA), a sense
lncRNA, which competitively binds to antisense GMAN RNA (GMAN-AS), resulting in
polymer formation of the downstream Ephrin A1 mRNA and thus increasing the
translation of Ephrin A1 mRNA. This promotes the invasive activity and metastasis of GC
cells. Knocking out GMAN or Ephrin A1 in GC cell lines reduces their invasive activity and
ability to form metastases in mice [44].
Competitive endogenous RNA (ceRNA)

It has become increasingly clear that multiple RNA transcripts, such as ncRNAs, IncRNAs, pseudogenes, and circular RNAs, can be act as ceRNAs, also known as “molecular sponges” of miRNAs, to regulate the expression of miRNA target genes through miRNA response elements (MREs) [45]. It is worth noting that a variety of IncRNAs involved in the progress of GC can be regulated in this manner, and IncRNA–miRNA–mRNA network alterations are considered indispensable mechanisms in GC. There are several examples of IncRNAs functioning as sponges and therefore oncogenes or tumor suppressor genes in GC.

KCNQ1OT1, an miR-504 sponge that targets CDK16 (cyclin-dependent kinase 16) in HCC and CCNE2 (cyclin E2), and a miR-370 sponge, in glioma can also act as an ceRNA via neutralizing miR-9. This promotes the progression of GC by regulating the expression of Lim homeobox transcription factor 1 (LMX1A) [46,47]. LMX1A is a tumor suppressor and member of the LIM-homeodomain (LIM-HD) family [48], which is downregulated in cancers [49]. Moreover, in GC cells in which LMX1A is knocked out, over-expressing or silencing KCNQ1OT1 is completely ineffective, consistent with the notion that KCNQ1OT1 participates in GC progression by regulating the expression of miR-9-LMX1A [50]. Another IncRNA that can control the progression of GC by regulating the miR-9-LMX1A axis is LINC00682. Ectopic over-expression of LINC00682 can downregulate miR-9 and upregulate LMX1A, as well as decrease GC cell survival, proliferation, migration, and invasion [51].

The level of expression of chemokine (CXCmotif) ligand (CXCL12) was found to be significantly increased in GC tissues with high COL1A1-014 expression. Bioinformatics analysis revealed that the two genes have complementary sequences for miR-1273H-5P; COL1A1-014 might act as a ceRNA and compete with CXCL12 to bind with miR-1273h-5p, thus inhibiting the degradation of CXCL12 by miR-1273H-5P and promoting GC progression. Additionally, BGC-823 cells over-expressing COL1A1-014 also exhibited strong colony-forming ability, which may reflect the degree of malignancy and have important significance for prognosis [52].
MYOSLID, found to be elevated in GC, is mainly concentrated in the cytoplasm [53]. MCL-1 is a member of the anti-apoptotic BCL2 family that is over-expressed in many tumor types and protects tumor cells from invasion [54,55]. MYOSLID promotes cell proliferation and inhibits apoptosis by regulating the miR-29C-3P-MCL-1 axis and miR-29C-3P thus acts as a tumor inhibitor in GC [53].

Neuroepithelial cell transforming gene 1 (NET1) is a RHOA (Ras homolog gene family member A) specific guanine exchange factor (GEF); RHOA is one of the most widely studied members of the RHO GTPase family of proteins. The RHOA signaling pathway is involved in biological processes such as cell proliferation and apoptosis and is related to the invasion and metastasis of tumors [56]. CTC-497E21.4, involved in post-transcriptional regulation in the cytoplasm, competes with miR-22 and regulates the expression of NET1 through the RHOA signaling pathway [57]. Low miR-22 expression also promotes extracellular matrix (ECM) remodeling and epithelial-to-mesenchymal transition (EMT) by enhancing matrix metalloproteinase (MMP)14 and Snail expression in GC invasion and metastasis [58].

**LncRNAs act on proteins**

In addition to the above-mentioned complex regulations at the epigenetic and transcriptional levels, lncRNAs can also interact with functional proteins in the most direct manner. By regulating the activity and function of proteins, influencing the interactions between proteins, or changing the localization of proteins in cells, and even functioning as structural components, lncRNAs participate in the development of cancers.

Desmoplakin (DSP), the first discovered member of the Plakin family of proteins and a significant component of desmosomal plaques, is considered to play an important role in the early stages of tumor development [59]. There is a negative correlation between MIR4435-2HG and DSP, with the former inhibiting the latter, which stimulates the growth and metastasis of GC cells by inducing EMT and Wnt/βcatenin signaling. Further, the interaction between DSP and MIR4435-2HG has been verified by RNA pull-down test, and the positive rather than the negative MIR4435-2HG pull-down protein complex was
KRT19P3 (Keratin 19 Pseudogene 3) can regulate the activity and enhance the stability of COPS7A in GC by binding directly to it. COPS7A belongs to the CSN complex and is composed of eight subunits designated CSN1–CSN8. Abnormal expression of CSN reportedly affects key processes in carcinogenesis such as signal transduction, cell cycling, and apoptosis. COPS7A enhances de-ubiquitination of IκBα (inhibitor of nuclear factor kappa-B (NF-κB)), by the CSN-associated de-ubiquitinase USP15; thus, KRT19P3 suppresses the NF-κB signaling pathway in a COPS7A-dependent manner [61,62]. As a consequence, decreased expression of KRT19P3 is associated with tumor size, TNM staging, Lauren grade, lymph node metastasis, and poor prognosis.

LINC00707, 3087 bp long, was previously reported to be an important oncogene in lung adenocarcinoma [63]. Recently, it has been found that LINC00707, which also functions as an oncogene in GC, can interact with HuR, which itself interacts with 3′UTR regions of mRNA after transcription and enhances its stability; the resulting LINC00707–HuR can further combine with VAV3/F11R mRNAs to increase their stability [64,65]. There is abundant evidence that VAV3 plays an important role in cell adhesion, angiogenesis, and cell differentiation, and F11R, also known as junctional adhesion molecule A (JAM-A), significantly influences epithelial cell morphology and migration [66,67].

In addition to HuR, RNA-binding protein YBX1 (Y-box-binding protein 1) also participates in the regulation of IncRNAs in GC. YBX1 is a protein with a common nucleic acid-binding domain in the gene promoter CCAA T-box, which influences many cell processes, including transcription and translation [68]. HOXC-AS3 potentially regulates a group of genes related to cell proliferation and migration of GC, including MMP7, WNT10B, HDAC5 and others, by binding to YBX1 [69]. Among these, HDAC5 is a key gene belonging to the histone deacetylase (HDAC) family. Because histone acetylation and deacetylation are essential for chromatin remodeling and gene expression, imbalances in these reactions lead to disorderly expression of many cancer-related genes [70]. In addition to HDAC5, numerous genes related to tumorigenesis are also
regulated in a similar manner by HOXC-AS3 [69].

Table 1. Multi-functional roles of lncRNAs in gastric cancer

<table>
<thead>
<tr>
<th>Mode of mechanism</th>
<th>LncRNA</th>
<th>Expression</th>
<th>Molecular mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Histone Modification</td>
<td>UCA1</td>
<td>up</td>
<td>Mediates the trimethylation of H3K27 in promoters of p21 and SPRY1 by binding to EZH2.</td>
</tr>
<tr>
<td></td>
<td>MNX1-AS1</td>
<td>up</td>
<td>Promotes GC progression through EZH2/BTG2 and miR-6785-5p/BCL2 axis.</td>
</tr>
<tr>
<td></td>
<td>SNHG3</td>
<td>up</td>
<td>Regulates neighboring MED18 gene methylation.</td>
</tr>
<tr>
<td></td>
<td>ARHGAP27P1</td>
<td>down</td>
<td>Epigenetically regulates p15 and p16.</td>
</tr>
<tr>
<td></td>
<td>GCLNC1</td>
<td>up</td>
<td>Acts as a modular scaffold of WDR5 and KAT2A complexes.</td>
</tr>
<tr>
<td></td>
<td>GCAWK1</td>
<td>up</td>
<td>Acts as a molecular scaffold of WDR5/KAT2A complexes.</td>
</tr>
<tr>
<td></td>
<td>LINC00673</td>
<td>up</td>
<td>Acts as a scaffold for LSD1 and EZH2.</td>
</tr>
<tr>
<td></td>
<td>FEZF1-AS1</td>
<td>up</td>
<td>Represses the expression of P21 via binding with LSD1.</td>
</tr>
<tr>
<td></td>
<td>HOTAIR</td>
<td>up</td>
<td>Recruits the PRC2 complex to silence target gene via H3K27me3 modification.</td>
</tr>
<tr>
<td></td>
<td>XIST</td>
<td>up</td>
<td>Interacts with EZH2 to suppress.</td>
</tr>
<tr>
<td>Type</td>
<td>Gene</td>
<td>Regulation</td>
<td>Function</td>
</tr>
<tr>
<td>-------------</td>
<td>-------------</td>
<td>------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>DNA</td>
<td>SNHG1</td>
<td>up</td>
<td>Promotes DNMT1 expression</td>
</tr>
<tr>
<td>methyl</td>
<td>MEG3</td>
<td>down</td>
<td>DNA methylation affects the expression of MEG3 and its targeting miR-181a-5p</td>
</tr>
<tr>
<td>mRNA</td>
<td>MACC1-AS1</td>
<td>up</td>
<td>Stabilizes MACC1 mRNA</td>
</tr>
<tr>
<td>translation</td>
<td>GMAN</td>
<td>up</td>
<td>Promotes translation of ephrin A1 messenger RNA</td>
</tr>
<tr>
<td>KRT7-AS</td>
<td></td>
<td>up</td>
<td>Stabilizes KRT7 mRNA</td>
</tr>
<tr>
<td>CeRNA</td>
<td>KCNQ1OT1</td>
<td>down</td>
<td>KCNQ1OT1/miR-9/LMX1A</td>
</tr>
<tr>
<td></td>
<td>LINC00682</td>
<td>down</td>
<td>LINC00682/miR-9/LMX1A</td>
</tr>
<tr>
<td></td>
<td>COL1A1-014</td>
<td>up</td>
<td>COL1A1-014/miR-1273h-5p/CXCL 12</td>
</tr>
<tr>
<td></td>
<td>MYOSLID</td>
<td>up</td>
<td>MYOSLID/miR-29c-3p/MCL-1</td>
</tr>
<tr>
<td></td>
<td>CTC-497E21.</td>
<td>up</td>
<td>CTC-497E21.4/miR-22/NET1</td>
</tr>
</tbody>
</table>
LINC00346  up  LINC00346/miR-34a-5p/CD44, [79] NOTCH1, AXL

UCA1  up  UCA1/miR-26a/b, miR-193a, [80] miR-214/PDL1

LINC01133  down  LINC01133/miR-106a-3p/APC [81]
MT1JP  down  MT1JP/miR-92a-3p/FBXW7 [82]
LINC01939  down  LINC01939/miR-17-5p/EGR2 [83]
H19  up  H19/miR-22-3p/Snail [84]
UCA1  up  UCA1/miR-203/ZEB2 [85]
HNF1A-AS1  up  HNF1A-AS1/miR-661/CDC34 [86]
UFC1  up  UFC1/miR-498/Lin28b [87]
GCRL1  up  GCRL1/miR-885-3p/CDK4 [88]
SMARCC2  down  SMARCC2/miR-551b-3p/TMPRSS [89] 4

BC032469  up  BC032469/miR-1207-5p/hTERT [90]

LncRNAs act on proteins

MIR4435-2HG  up  Binds to DSP and inhibits its expression [60]
KRT19P3  down  Enhances COPS7A protein stability in GC cells [62]
LINC00707  up  Interacts with mRNA stabilizing protein HuR [65]
HOXC-AS3  up  Binds to YBX1 [69]
SNHG12  up  Increases the phosphorylation of PI3K by directly binding to it [91]
SEMA3B-AS1  down  Interacts with MLL4 [92]
pancEts-1  up  Directly interacts with NONO to increase its interaction with ERG [93]
### Relationships between lncRNAs and the hallmarks of gastric cancer

GC carcinogenesis is a multi-step process influenced by many different factors, such as heredity and environment. A variety of complex cancers share several common characteristics, as identified by Hanahan and Weinberg, including sustaining proliferation signals, avoidance of growth inhibitors, resistance to cell death, replicative immortality, induction of angiogenesis, activation of invasion, and metastasis [96]. Each factor contributes to the formation of large numbers of abnormal cells that grow unchecked. In recent years, the exploration and elucidation of the structures and functions of lncRNAs have shown these to be important molecular signal transduction media in cancer development in that they regulate the expression of specific genes and corresponding signal pathways. Below, we will discuss the regulatory role of some lncRNAs in GC (Table 2).

### LncRNAs and proliferation

Sustained proliferation is a typical characteristic of cancer cells. Complex molecular pathways and dynamic crosstalk between tumor cells and their microenvironment maintain these characteristics. The ability of a cancer cell to sustain chronic proliferation is its most fundamental characteristic, achieved by the maintenance of growth signals via the autocrine and paracrine growth factor pathways [97]. Normal tissues strictly control the production and release of growth-promoting signals, which in turn control cell growth and division to ensure homeostasis and thus maintain normal structure and function [96]. Cancer cells regulate these signals to mediate tumor growth, and lncRNAs participate in this process by regulating the growth factors or receptors (Figure 2a).

<table>
<thead>
<tr>
<th>lncRNA</th>
<th>Regulation</th>
<th>Interaction</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>GALNT5</td>
<td>up</td>
<td>Binds with HSP90</td>
<td>[94]</td>
</tr>
<tr>
<td>HOTAIR</td>
<td>up</td>
<td>Interacts with Mex3b</td>
<td>[95]</td>
</tr>
</tbody>
</table>
Epidermal growth factor receptor (EGFR) belongs to the family of receptor tyrosine kinases (RTK), commonly over-expressed in tumors and considered as a driver and regulator of tumorigenesis [98]. Linc00152 in the cytoplasm can bind directly to EGFR, resulting in increased EGFR expression and activation of the EGFR signaling pathway. In addition, the inhibition of p-EGFR, p-AKT, and p-PI3K (phosphoinositide 3-kinase) in cells treated with Linc00152 shRNA suggested that Linc00152 might induce the constitutive activation of EGFR signaling and activate the downstream PI3K/AKT signaling pathway [99]. AK123072 is an intron antisense IncRNA that is frequently upregulated by hypoxia in GC. In hypoxia-induced AK123072 over-expression in GC cells, the CPG island methylation of the EGFR gene is significantly decreased, leading to its increased expression, thereby promoting the spread of cancer cells. Moreover, AK123072 can promote GC migration and invasion by increasing the stability and expression of c-Myc mRNA [100].

In addition to their remarkable ability to induce and maintain positive growth stimulating signals, cancer cells must also avoid the powerful mechanisms that negatively regulate cell proliferation. Several tumor suppressors, such as the classic p53, Rb, and PTEN [101,102], have been found to regulate the cell cycle and inhibit cell growth and proliferation in different ways. Characteristically, they are inactivated in cancer cells. Some IncRNAs affect the growth and proliferation of GC cells by directly or indirectly altering the expression of tumor suppressor factors (Figure 2b), for example, p53, a key gatekeeper of the cell. P53 is a stress-induced transcription factor, which can promote cell cycle arrest, apoptosis, and senescence [103]. The oncogene ZFPM2-AS1, which is an important upstream regulator of the MIF/P53 axis, promotes the proliferation and inhibits apoptosis of GC cells. The mechanism of ZFPM2-AS1 action involves regulating the expression and subcellular localization of p53 to inactivate the p53 signaling pathway through its physical interaction with MIF at the translational or post-translational level [104]. Previous studies have shown that MIF, a tumor promoter, decreases the stability of the p53 protein and prevents its nuclear translocation by physically associating with it [105]. Furthermore, it was found that the accumulation of MIF protein induced by
ZFPM2-AS1 in GC cells was not due to increased protein synthesis, but was due to increased protein stability [104]. OncIncRNA-626 located on chromosome 11 can also affect p53 expression. It interacts specifically with serine- and arginine-rich splicing factor 1 (SRSF1), increasing its stability and upregulating it in GC tissues. RSF1, also known as SF2/ASF, which plays a regulatory role in many cancers, is a member of the SR family. It has two domains, RRM1 and RRM2, where RRM2 domain is the dominant binding site of OncIncRNA-626 [106,107]. Thus, OncIncRNA-626 may exert its biological function through the SRSF1/p53 pathway and may be a potential therapeutic target in GC [107].

Some lncRNAs also act on the tumor suppressor PTEN, whose frequent deletion in cancer suggests its physiological importance. PTEN governs a variety of biological processes by inhibiting the PI3K/AKT-mammalian target of rapamycin (mTOR) pathway through its lipid phosphatase activity; this includes maintaining genomic stability, cell survival, migration, proliferation, and metabolism [108]. TUBA4B, a ceRNA, was found to physically bind to and chelate miR-214 and miR-216a/b, thus increasing the expression of the common downstream target PTEN, decreasing the expression of p-PI3K and p-AKT, and thereby leading to the inactivation of the PI3K/AKT signaling pathway. Moreover, the weakened cell malignancy phenotype induced by TUBA4B was evidently rescued by PTEN silencing and AKT activation [109]. LINC00470, mainly distributed in the cytoplasm, can bind to PTEN mRNA and promote its degradation. This process, mediated by N6-methyladenosine (m6A) writer METTL3, enhanced its m6A methylation level resulting in high levels of m6A RNA and METTL3 in GC. It was also found that the LINC00470–METTL3-mediated degradation of PTEN mRNA was dependent on the human YTH domain family 2 (YTHDF2), an m6A reader protein [110]. LncRNAs that influence m6A modification play a key role in regulating cancer progression. For example, IncRNA GAS5-AS1 inhibits the growth of cervical cancer by interacting with RNA demethylase ALKBH5 to increase GAS5 stability and decrease GAS5 m6A modification [111]. It has also been reported that LINC00470 binds to fused in sarcoma (FUS) and AKT, which anchors FUS in the cytoplasm and activates AKT. Subsequently, the expression of ELFN2 is upregulated, thus affecting glycolysis, inhibiting autophagy, and
promoting tumorigenesis [112,113]. Moreover, the mechanism of LINC00470 action on tumor suppressor PTEN also supports its influence on gastric cancer.

Finally, the key tumor suppressor Rb can also be regulated by IncRNAs. The Rb protein integrates signals from different extracellular and intracellular sources and determines whether the cell should continue its growth and division cycle [101]. When cells are stimulated by growth-promoting signals, cyclin D/CDK4 is induced to phosphorylate Rb1, so that the Rb–E2Fs complex releases E2Fs and cells can enter S-phase [114]. Linc00441, a carcinogenic IncRNA, recruits DNMT1 into the Rb1 promoter and inhibits the expression of RB1 in GC cells, leading to their proliferation [77]. In addition to the previously mentioned effects on the expression of ATG4B, MEG3 can inhibit MDM2, increase the active form of Rb, and then enhance the interaction between Rb and transcription factor E2Fs to block the transcription of its target gene. Additionally, MEG3 influences Rb via the regulation of RNA–protein binding or CDKN4A [115].

Telomerase, a DNA polymerase that adds telomeric repeats to the ends of telomeric DNA, maintains telomere length and protects the chromosome ends, crucial for the development and survival of tumors [96,116]. Telomerase reverse transcriptase (hTERT), a catalytic subunit of telomerase, plays an important role in maintaining telomere length, maintaining cell division, and replication [117]. A novel endogenous IncRNA BC032469, which is highly expressed in GC tissue, can combine directly with, and effectively act as a sponge for, miR-1207-5p to regulate hTERT expression and thus the cell cycle in the G0/G1 phase. Therefore, upregulation of BC032469 is associated with larger tumor volume, poor differentiation, and shorter survival time in patients with GC (Figure 2c) [90].
Some IncRNAs mainly regulate the ability of tumors to grow by regulating growth factors or receptors. (b) Some IncRNAs affect the growth and proliferation of gastric cancer cells by directly or indirectly altering the expression of tumor suppressor factors. (c) Some IncRNAs play a role in the proliferation of gastric cancer cells by affecting telomerase activity.

**LncRNAs and resistance to cell death**

Programmed cell death (PCD) refers to apoptosis, autophagy, and programmed necrosis, all of which are mediated by intracellular programming. The fate of tumor cells can be determined by the balance between cell death and survival mediated by PCD. Abnormal PCD processes can also result in faulty proliferation patterns of tumor cells. The cascade of events due to IncRNAs involved in tumorigenesis and malignant transformation are mostly related to the first two forms, namely apoptosis and autophagy (Figure 3). Another newly-described IncRNA, XIAP-AS1, mainly located in the nucleus, is
transcribed from the first intron of the complementary chain of the XIAP (X-linked apoptosis inhibitor) gene. XIAP binds to the BIR2 and BIR3 domains of caspase-3 and caspase-9, respectively, to inhibit their activation and block apoptosis. Full-length XIAP-AS1 RNA interacts with SP1, which participates in the transcription of XIAP, and thus affects the apoptosis process mediated by XIAP. Furthermore, the downregulation of XIAP-AS1 promotes the apoptosis of gastric tumor cells induced by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) [118,119]. TRAIL, a member of the TNF family of cytokines, induces apoptosis through both mitochondrial-dependent and death receptor pathways in tumor cells, preferentially killing tumor cells but not normal cells [120]. Therefore, XIAP-AS1 affects the apoptosis of GC cells by influencing the transcription of XIAP and acting as a potential target for TRAIL. Silencing the expression of TINCR inhibits cell proliferation, colony formation, tumorigenicity, and can promote cell apoptosis as reported for SGC7901 and BGC823 cell lines. TINCR binds to STAU1 protein, which can induce mRNA degradation, and the resulting complex affects the expression of Kruppel-like factor (KLF)2 through this STAU1-mediated mRNA degradation (SMD) [121]. SMD is a translation-dependent mechanism that occurs when STAU1, together with the nonsense-mediated mRNA decay factor UPF1, binds at a location downstream of the termination codon [122]. SMD is a translation-dependent mechanism that occurs when STAU1, together with the nonsense-mediated mRNA decay factor UPF1, binds at a location downstream of the termination codon [123]. When the expression of KLF2 is regulated by TINCR, KLF2 further regulates the transcription and expression of the CDK genes CDKN1A/P21 and CDKN2B/P15, thus affecting the proliferation and apoptosis of GC cells [121]. Further understanding of the function and clinical significance of TINCR and its target genes KLF2, CDKN1A/P21, and CDKN2B/P15 may be helpful for early diagnosis and treatment of GC. LINC01419 silencing inhibits the activation of the PI3K/AKT1/mTOR pathway, as demonstrated by reduced phosphorylation of AKT1 and mTOR, thus promoting autophagy of GC cells as well as inhibiting tumor growth and metastasis. These findings offer a new perspective in that the downstream PI3K/AKT1/MTOR axis mediated by LINC01419 may be a new
target for GC therapy [124].

**Figure 3.** Some lncRNAs and their molecular partners or genomic targets play their key roles in resistance to cell death in gastric cancer.

**LncRNAs and metastasis**

EMT, considered to be an important mechanism of tumor metastasis, is a cell program that is crucial for embryogenesis and wound healing, but also furthers malignant progression and can facilitate tumor initiation and metastatic potential of cancer cells. The process of EMT encompasses the disintegration of intercellular connections, reorganization of the actin cytoskeleton, and enhancement of cell viability and invasive capacity [125]. The destruction of tight junctions is related to the loss of the epithelial marker E-cadherin and the acquisition of mesenchymal markers N-cadherin and vimentin [126]. A variety of lncRNAs is involved in the development of GC by regulating EMT and metastasis (Figure 4).

Four molecular subtypes of GC can be defined on the basis of microsatellite stability (MSS) or instability (MSI) and p53 status, namely, MSS/TP53 + , MSS/TP53 -, MSI, and
MSI/EMT [127]. Zhang et al. quantified IncRNA MAGI2-AS3 in these four subtypes of GC and reported that it was extremely high in the MSS/EMT subtype, suggesting that MAGI2-AS3 is associated with EMT. Moreover, miR-141 and miR-200a are known to be negative regulators of the ZEB1 gene and EMT pathway; MAGI2-AS3, mainly located in the cytoplasm, promotes tumor metastasis by binding miR-141/200a to maintain downstream ZEB1 over-expression, which is a well-accepted core factor regulating the EMT process [128,129].

It was confirmed that knockout of DLX6-AS1 inhibits the expression of N-cadherin, MMP9, and SLUG, as well as promoting the expression of E-cadherin. In addition, the distribution of the actin cytoskeleton and the presence of filamentous pseudopodia were significantly reduced when DLX6-AS1 was knocked out. The specific mechanism of its action involves DLX6-AS1 functioning as an endogenous cancer-promoting ceRNA that upregulates OCT1 by binding with miR-204-5p, which is downregulated in GC and inhibits tumor progression through various mechanisms. The 3-UTR region of OCT1 contains a potential binding site for miR-204-5p, and has been found to be a transcription factor contributing to carcinogenesis in GC and precancerous lesions. In addition, OCT1 was confirmed to enhance the expression of DLX6-AS1 by targeting the promoter region, revealing a positive feedback loop (OCT1/DLX6-AS1/miR-204-5p/OCT1) which promotes the progress of GC and EMT [130]. Together, DLX6-AS1 is upregulated in GC tissues and cell lines and is associated with distant metastasis, T3/T4 invasion, and poor clinical prognosis.
Figure 4. Some IncRNAs play their important roles in the metastasis and invasion of gastric cancer by participating in the EMT process.

LncRNAs and DNA damage

An underlying feature of cancers is genomic instability, which is associated with a greater tendency to trigger DNA damage responses (DDR) [131]. The DDR which involves a complex regulatory network of lncRNAs may also participate in cancer progression (Figure 5A). For example, the NF-κB-HOTAIR axis links DDR to ovarian carcinogenesis [132], and LINC00261, an epigenetically regulated tumor suppressor, is critical for the activation of DDR in lung cancer [133].

In GC, PANDAR (promoter of CDKN1A antisense DNA damage-activated RNA), whose expression is induced by p53, is also a direct transcriptional target of the p53 protein. PANDAR is induced in response to DNA damage via inhibition of the function of the transcription factor nuclear transcription factor Y subunit alpha (NFYA). Upregulated HOTAIR inhibits the expression of p53 by enhancing the p53 promoter H3K27me3, while
overexpression of PANDAR increases the stability of p53 in response to DNA damage [134].

Noncoding RNA activated by DNA damage (NORAD), a highly conserved IncRNA essential for mitotic cell division, plays a key role in DNA replication and DDR. NORAD responds to DNA damage by regulating the activity of the RNA-binding proteins PUM2 and PUM1 in order to maintain genomic integrity [135]. NORAD expression is upregulated in GC, which can also significantly increase FOXO6 abundance and promote tumor progression. Mechanistically, NORAD acts as a ceRNA sponge for miR-608 to upregulate the expression of FOXO6 that in turn enhances the tumorigenicity of GC cells by upregulating the oncogene c-Myc [136].

Figure 5. (A) DNA damage involves a complex regulatory network and some IncRNAs can also participate in the regulation of DDR to affect cancer progression in gastric cancer. (B) Some IncRNAs have been shown to play a role in the development of gastric cancer by regulating angiogenesis.
**LncRNAs and angiogenesis**

Angiogenesis is an essential feature of cancer, providing nutrients and oxygen for tumor growth. VEGFA, a major regulator of angiogenesis, can induce the proliferation and migration of endothelial cells to form new blood vessels [137] (*Figure 5B*).

PVT1 is considered an oncogene interacting with different proteins and playing a variety of roles in carcinogenesis. In GC, PVT1 promotes cell proliferation by binding to EZH2 and also promotes migration and invasion by interacting with FOXM1 [138]. In addition, PVT1 can bind to nuclear p-STAT3 to form a complex that protects p-STAT3 from degradation in the polyubiquitin-proteasome, and then activates the STAT3/VEGFA axis to induce angiogenesis. Activated STAT3 in turn triggers PVT1 transcription, maintaining the oncogenicity of the PVT1/STAT3/VEGFA axis [139]. Therefore, the upregulation of lncRNA PVT1 is closely related to the high density of microvessels in GC and its poor prognosis; it can promote the proliferation of GC cells in vitro and tumor growth and angiogenesis in vivo.

The KLK4 gene is a direct target of LINC01314 that is poorly expressed in GC. KLK4 is a subunit of a serine endopeptidase found in a variety of cells and tissues, which is essential for diversified pathophysiological development, including angiogenesis in cancers. Over-expression of LINC01314 or KLK4 silencing suppresses angiogenesis in GC cells through negative regulation of the Wnt/β-catenin signaling pathway. At the same time, the tumor weight, the microvessel density of the transplanted tumor and, most importantly, the expression of both VEGF-C and VEGFR-3 were all decreased. In addition, LINC01314 over-expression can decrease N-cadherin and increase E-cadherin expression, therefore presumably it can also inhibit GC migration [140,141].

**LncRNAs and the immune response**

The differentiation and activation of innate and adaptive immune cells is highly dependent on a coordinated set of transcriptional and post-transcriptional events. LncRNAs are now emerging as important regulators of the differentiation and activation of immune cells. They do not directly encode innate or adaptive immune proteins but
regulate the differentiation and function of immune cells, such as dendritic cell activity, T cell ratios and metabolism [142]. A dynamic equilibrium exists between the immune system and the malignant tumor, which can evade immune clearance and proliferate pathologically. Studies are increasingly revealing that IncRNAs have regulatory roles in the immune system, providing a reliable research basis for IncRNAs to participate in the immunotherapy of GC (Figure 6A). For instance, in addition to the effects of UCA1 on chromatin in GC, it can also act as a "miRNA sponge" for miR-193a and miR-214, reducing their targeting of the 3′ UTR of PDL1 and thus facilitating PDL1 expression [80]. PDL1 is a transmembrane protein, overexpressed in cancer cells, which suppresses the host's immune system by binding to PD1 on activated T cells, B cells, and bone marrow cells [143]. Therefore, UCA1, which protects PDL1 from the inhibitory effect of miRNAs and promotes immune escape of GC cells, may be a potential target, providing a new direction for immunotherapy of GC.

In general, based on the theory of their binding with miRNAs and proteins, many types of IncRNAs found in exosomes could participate in the process of tumorigenesis as tumor antigens to activate anti-tumor immune response, and may thus be considered as targets for immunotherapy. However, the regulatory mechanism of existing RBPs such as IncRNA-miRNA-mRNA on immune regulation of GC is still unclear and requires further exploration.
Some lncRNAs play the regulatory roles in the immune system and participate in the balance between the immune system and gastric cancer cells. Some lncRNAs play the key roles in maintaining the gastric cancer stem cell phenotype by influencing their expression.

**LncRNAs and the stemness of gastric cancer**

CSCs (cancer stem cells), recognized as tumor-initiating cells, are tumor cells with the capacity for self-renewal, metastasis, tumorigenicity, which exhibit chemotherapy resistance [144] (Figure 6B). Numerous studies have confirmed the genetic homology of lncRNA LOXL1 antisense RNA 1 (LOXL1-AS1) in various human cancers. Thus, it was confirmed that LOXL1-AS1 knockdown decreased the expression of stem cell factors such as Nanog, SOX2, and OCT4. Independently, MKN45 cells with lower expression of LOXL1-AS1 were found to be more sensitive to cisplatin therapy, which further supported the notion that LOXL1-AS1 promotes the maintenance of CSC features in GC [145]. In GC cells over-expressing SPRY4-IT1, CSC markers, including CD73, CD146, and ALDH1, were all significantly elevated. In contrast, inhibition of SPRY4-IT1 reduced the self-renewal ability of BGC823 cells and significantly reduced the expression of CSC markers [146]. These results consistently show that SPRY4-IT1 plays a role in maintaining the GC stem cell phenotype.
### Table 2. The relationships between lncRNAs and the hallmarks of gastric cancer

<table>
<thead>
<tr>
<th>Function</th>
<th>LncRNA</th>
<th>Expression</th>
<th>Target</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>LncRNAs and proliferation</td>
<td>Linc00152</td>
<td>up</td>
<td>EGFR</td>
<td>[99]</td>
</tr>
<tr>
<td></td>
<td>AK123072</td>
<td>up</td>
<td>EGFR</td>
<td>[100]</td>
</tr>
<tr>
<td></td>
<td>ZFPM2-AS1</td>
<td>up</td>
<td>MIF/P53</td>
<td>[104]</td>
</tr>
<tr>
<td></td>
<td>OncIncrNA-626</td>
<td>up</td>
<td>SRSF1/p53</td>
<td>[107]</td>
</tr>
<tr>
<td></td>
<td>GAS5</td>
<td>up</td>
<td>eIF4A3/P53</td>
<td>[147]</td>
</tr>
<tr>
<td></td>
<td>PWRN1</td>
<td>down</td>
<td>miR-425-5p/PTEN/Akt/MDM2/p53</td>
<td>[148]</td>
</tr>
<tr>
<td></td>
<td>AK023391</td>
<td>up</td>
<td>PI3K/Akt/p53</td>
<td>[149]</td>
</tr>
<tr>
<td></td>
<td>TUBA4B</td>
<td>down</td>
<td>miR-214 and miR-216a/b/PTEN</td>
<td>[109]</td>
</tr>
<tr>
<td></td>
<td>LINC00470</td>
<td>up</td>
<td>METTL3/PTEN</td>
<td>[110]</td>
</tr>
<tr>
<td></td>
<td>PCAT-1</td>
<td>up</td>
<td>EZH2/PTEN</td>
<td>[150]</td>
</tr>
<tr>
<td></td>
<td>Linc00441</td>
<td>up</td>
<td>RB1</td>
<td>[77]</td>
</tr>
<tr>
<td></td>
<td>MEG3</td>
<td>up</td>
<td>P53,RB</td>
<td>[151]</td>
</tr>
<tr>
<td></td>
<td>BC032469</td>
<td>up</td>
<td>BC032469/miR-1207-5p/hTER</td>
<td>[90]</td>
</tr>
<tr>
<td>LncRNAs and resistance to cell death</td>
<td>XIAP-AS1</td>
<td>up</td>
<td>XIAP</td>
<td>[118]</td>
</tr>
<tr>
<td></td>
<td>TINCR</td>
<td>up</td>
<td>KLF2</td>
<td>[121]</td>
</tr>
<tr>
<td></td>
<td>LINC01419</td>
<td>up</td>
<td>PI3K/Akt1/mTOR</td>
<td>[124]</td>
</tr>
<tr>
<td></td>
<td>HAGLROS</td>
<td>up</td>
<td>miR-100-5p/mTOR , mTORC</td>
<td>[152]</td>
</tr>
<tr>
<td></td>
<td>MAGI2-AS3</td>
<td>up</td>
<td>MAGI2-AS3/miR-141/200a/ZEB1</td>
<td>[128]</td>
</tr>
<tr>
<td>LncRNAs and metastasis</td>
<td>DLX6-AS1</td>
<td>up</td>
<td>miR-204-5p/OCT1</td>
<td>[130]</td>
</tr>
<tr>
<td></td>
<td>HULC</td>
<td>up</td>
<td>miR-9-5p/MYH9</td>
<td>[153]</td>
</tr>
<tr>
<td>LncRNA</td>
<td>Expression</td>
<td>Target/Pathway</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>------------</td>
<td>---------------------------------------------------</td>
<td>-----------</td>
<td></td>
</tr>
<tr>
<td>DLX6-AS1</td>
<td>up</td>
<td>FUS-regulated MAP4K1</td>
<td>[154]</td>
<td></td>
</tr>
<tr>
<td>SNHG16</td>
<td>up</td>
<td>DKK3</td>
<td>[155]</td>
<td></td>
</tr>
<tr>
<td>ELIT-1</td>
<td>up</td>
<td>TGFβ/Smad3 signaling</td>
<td>[156]</td>
<td></td>
</tr>
<tr>
<td>LINC01133</td>
<td>up</td>
<td>miR-106a-3p/APC</td>
<td>[81]</td>
<td></td>
</tr>
<tr>
<td>MEG3</td>
<td>down</td>
<td>E-cadherin,Vimentin</td>
<td>[157]</td>
<td></td>
</tr>
<tr>
<td>LncRNA-ATB</td>
<td>up</td>
<td>MiR - 141 - 3p/TGFβ2</td>
<td>[158]</td>
<td></td>
</tr>
<tr>
<td>LINC00675</td>
<td>down</td>
<td>vimentin</td>
<td>[159]</td>
<td></td>
</tr>
<tr>
<td>SNAI1</td>
<td>up</td>
<td>CDH1</td>
<td>[160]</td>
<td></td>
</tr>
<tr>
<td>LncRNAs</td>
<td>PANDAR</td>
<td>NFYA, p53/CDKN1A</td>
<td>[134]</td>
<td></td>
</tr>
<tr>
<td>and DNA</td>
<td>NORAD</td>
<td>miR-608</td>
<td>[136]</td>
<td></td>
</tr>
<tr>
<td>damage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LncRNAs</td>
<td>PVT1</td>
<td>STAT3/VEGFA</td>
<td>[139]</td>
<td></td>
</tr>
<tr>
<td>and LINC01314</td>
<td>down</td>
<td>KLK4</td>
<td>[140]</td>
<td></td>
</tr>
<tr>
<td>angiogenesis</td>
<td>ZEB2-AS1</td>
<td>Wnt/β-catenin pathway</td>
<td>[161]</td>
<td></td>
</tr>
<tr>
<td>MEG3</td>
<td>down</td>
<td>MEG3/miR-21</td>
<td>[162]</td>
<td></td>
</tr>
<tr>
<td>LncRNAs</td>
<td>UCA1</td>
<td>miR-193a, miR-214/PDL1</td>
<td>[80]</td>
<td></td>
</tr>
<tr>
<td>and the</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>immune</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>response</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LncRNAs</td>
<td>LOXL1-AS1</td>
<td>LOXL1-AS1/miR-708-5p/SOX2</td>
<td>[145]</td>
<td></td>
</tr>
<tr>
<td>and the</td>
<td>SPRY4-IT1</td>
<td>SPRY4-IT1/miR-101-3p/AMPK</td>
<td>[146]</td>
<td></td>
</tr>
<tr>
<td>stemness</td>
<td>MACC1-AS1</td>
<td>MACC1-AS1/miR-145-5p</td>
<td>[163]</td>
<td></td>
</tr>
<tr>
<td>of GC</td>
<td>MALAT1</td>
<td>SOX2 mRNA</td>
<td>[164]</td>
<td></td>
</tr>
</tbody>
</table>

Potential clinical applications of LncRNAs in gastric cancer

LncRNAs as potential novel biomarkers

Because the majority of GC patients is diagnosed in the unsalvageable late stage,
there is an urgent need to identify effective biomarkers for early disease. Some established circulating tumor-specific biomarkers, such as carcinoembryonic antigen (CEA), carbohydrate antigen (CA)242, CA724, and serum pepsinogen (SPG), are known to be of limited use in the diagnosis of GC [165]. LncRNAs can be detected in a highly stable form in plasma and are therefore considered to be non-invasive and promising biomarkers for cancer diagnosis (Figure 7A and Table 3). Studies have shown that cancer cells secrete exosomes, and lncRNAs are enriched and stabilized within these [166]. Exosomes, small vesicles with a diameter of about 30–150 nm that act as mediators of cell-to-cell communication, play an important role in the process of tumor proliferation and metastasis by delivering carcinogens [167]. As carriers of information between cells, exosomes represent a hitherto unknown biological communication system. However, the biological function of secretory lncRNAs in GC remains to be elucidated. LncRNAs such as ZFAS1, HOTTIP, and IncUEGC1 can be detected in plasma exosomes; significant differences between cancer patients and healthy controls were observed in their expression and area under the curve (AUC) values by receiver operating characteristic curve (ROC) analysis [168-170]. Therefore, a large number of lncRNAs has been found to be suitable as noninvasive biomarker candidates for GC.

Evidence indicates that plasma H19 levels can be used to distinguish patients with early GC from controls, with clinical results that are as satisfactory as traditional tumor biomarkers. After further analysis of 70 patients and 70 controls, it was concluded that the level of plasma H19 in patients with GC was significantly higher than in healthy controls (p < 0.0001); ROC analysis revealed that the AUC was 0.838 (p < 0.001; sensitivity, 82.9%; specificity, 72.9%). Furthermore, the expression of H19 distinguished early-stage GC from controls with an AUC of 0.877 (sensitivity, 85.5%; specificity, 80.1%). It has also been demonstrated that plasma H19 levels are stable during direct treatment with RNase and are therefore stable and detectable in plasma [171]. Therefore, plasma H19 may be a promising tumor marker for GC; however, many questions remain to be resolved before these findings can be translated into clinically useful, non-invasive screening strategies for GC patients.
In addition to the use of a single lncRNA in the diagnosis of GC, studies have shown that multiple plasma lncRNA combinations can provide more effective diagnostic power for GC diagnosis. Genome-wide plasma lncRNA profiles were screened to identify promising GC lncRNA biomarkers, with the result that plasma levels of FAM49B-AS, GUSBP11, and CTDHUT in GC patients were found to be significantly higher than in healthy controls after validation with data from 446 subjects (AUC of 0.818, 95% CI, 0.772–0.864). Moreover, the combination of these three lncRNAs with CA242 or CA724 was superior to the traditional CA242 or CA724 biomarkers alone for GC diagnosis; however, the AUC value of the combination (0.784) was lower than for the three lncRNAs. These three lncRNAs were stable and detectable in human plasma, and their amounts decreased significantly on the 10th day after surgical resection [172]. Therefore, the plasma lncRNAs FAM49B-AS, GUSBP11, and CTDHUT have great potential as non-invasive biomarkers for the diagnosis of GC.

Evaluation of prognosis post-treatment is also essential for cancer patients. It can be used to assess the treatment status and provide evidence for adjusting treatment regimens. In recent years, together with tumor diagnostic biomarkers, the study of prognostic biomarkers related to lncRNAs has also made great progress (Table 4). CASC19, also known as CARLo-6 or LINC01245, an intergenic lncRNA 324 bp in length, is encoded on chromosome 8q24.21. An innovative genomic analytical method has combined different lncRNA expression profiles with WGCNA, and resulting in the definition of CASC19 as a key lncRNA related to the development and progression of AGC. CASC19 was found to be upregulated in AGC tissue, and to correlate positively with abnormal clinicopathologic parameters. These included pathologic T stage, TNM stage, lymph node metastasis, and poorer prognosis in patients with AGC. Overall survival of patients with high CASC19 expression was significantly worse than patients with low CASC19 expression. In this cohort of 375 patients, CASC19 was therefore suggested to be an independent prognostic factor for AGC overall survival [173]. Thus, CASC19 is involved in the development of AGC through the regulation of MAPK, calcium, Wnt, and insulin signaling pathways and may be a new prognostic marker and potential
therapeutic target for the disease.

The degree of over-expression of lncRNA NEAT1 in 140 GC specimens was found to be positively correlated with clinical stage, histological type, and distant or lymph node metastasis. Patients with low levels of NEAT1 had higher survival rates than those with high levels. Both univariate and multivariate analysis showed that overexpression of NEAT1 was an independent factor of poor prognosis in patients with GC. Knockout of NEAT1 significantly inhibited migration and invasion of GC cells in vitro and regulated the expression of EMT-related proteins. NEAT1 has also been shown to play a role in tumor development in esophageal cancer and glioma cells [174]. Thus, NEAT1 participates in the occurrence and development of GC and can be employed as a biomarker for its prognosis.

Figure 7. Potential clinical applications of lncRNAs in gastric cancer. (A) LncRNAs are enriched and stable in exosomes, can be detected in plasma samples, and are considered as non-invasive and promising biomarkers for gastric cancer. (B) LncRNAs can be involved in the complex regulatory network of therapy resistance in a number of ways, including affecting the amplification or overexpression of oncogenes, suppression of tumor suppressor genes, immune escape, apoptosis, autophagy, EMT, angiogenesis,
(C) Given the irreplaceable role of lncRNAs in the development of gastric cancer, targeting lncRNAs may produce reliable therapeutic results.

Table 3. LncRNAs as diagnostic biomarkers in gastric cancer

<table>
<thead>
<tr>
<th>Clinical application</th>
<th>LncRNA</th>
<th>Expression</th>
<th>Diagnosis accuracy</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostic biomarker</td>
<td>H19</td>
<td>up</td>
<td>AUC was 0.838; p&lt;0.001; sensitivity, 82.9%; specificity, 72.9%</td>
<td>[171]</td>
</tr>
<tr>
<td></td>
<td>FAM49B-AS,G</td>
<td>up</td>
<td>The combined area under curve of these lncRNAs was 0.818</td>
<td>[172]</td>
</tr>
<tr>
<td></td>
<td>USBP11</td>
<td>and</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CTDHUT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inc-GNAQ-6:1</td>
<td>down</td>
<td>AUC was 0.732</td>
<td>[175]</td>
</tr>
<tr>
<td></td>
<td>UCA1</td>
<td>up</td>
<td>AUC was 0.759; The sensitivity and specificity were 93.20% and 78.63%</td>
<td>[176]</td>
</tr>
<tr>
<td></td>
<td>B3GALT5-AS1</td>
<td>up</td>
<td>AUC was 0.816</td>
<td>[177]</td>
</tr>
<tr>
<td></td>
<td>HOTAIR</td>
<td>up</td>
<td>AUC was 0.8416; The sensitivity and specificity were 66.67 and 87.04%</td>
<td>[178]</td>
</tr>
<tr>
<td></td>
<td>IncUEGC1</td>
<td>up</td>
<td>AUC was 0.8406</td>
<td>[179]</td>
</tr>
<tr>
<td></td>
<td>PANDAR,</td>
<td>up</td>
<td>The AUC of the combinative diagnostic value of these three lncRNAs was 0.839</td>
<td>[180]</td>
</tr>
<tr>
<td></td>
<td>FOXD2-AS1,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>and SMARCC2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TINCR,</td>
<td>up</td>
<td>The AUC of the combinative diagnostic value of these five lncRNAs was 0.91</td>
<td>[181]</td>
</tr>
<tr>
<td></td>
<td>CCAT2,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AOC4P,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BANCR,</td>
<td>and</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 4. LncRNAs as prognostic biomarkers in gastric cancer

<table>
<thead>
<tr>
<th>Clinical application</th>
<th>LncRNA</th>
<th>Expression</th>
<th>Clinical significance</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prognostic biomarker</td>
<td>CASC19</td>
<td>up</td>
<td>Higher pathologic TNM stage, pathologic T stage, lymph node metastasis, and poor overall survival</td>
<td>[173]</td>
</tr>
<tr>
<td></td>
<td>SNHG6</td>
<td>up</td>
<td>Invasion depth, lymph node metastasis, distant metastasis and TNM stage</td>
<td>[182]</td>
</tr>
<tr>
<td></td>
<td>MIR100HG</td>
<td>up</td>
<td>TNM stage, tumor invasion, lymph node metastasis, and distant metastasis</td>
<td>[183]</td>
</tr>
<tr>
<td></td>
<td>Sox2ot</td>
<td>up</td>
<td>TNM stage, tumor depth, lymph node metastasis, and distant metastasis</td>
<td>[184]</td>
</tr>
<tr>
<td></td>
<td>MALAT1</td>
<td>up</td>
<td>Distant metastasis</td>
<td>[185]</td>
</tr>
<tr>
<td></td>
<td>NEAT1</td>
<td>up</td>
<td>Clinical stage, histological type, lymph node metastasis, and distant metastasis</td>
<td>[174]</td>
</tr>
<tr>
<td></td>
<td>SNHG8</td>
<td>up</td>
<td>Predicts poor prognosis, shorter survival time</td>
<td>[186]</td>
</tr>
<tr>
<td></td>
<td>CTD-2510F5.</td>
<td></td>
<td>Pathological grade, vascular or nerve invasion, AJCC TNM stage and OS, shorter MST</td>
<td>[187]</td>
</tr>
</tbody>
</table>
LncRNAs and resistance to therapy

Chemoradiotherapy (CRT) is the primary clinical treatment for multiple cancers including GC. Nevertheless, the development of acquired resistance to CRT greatly reduces its efficacy. Thus, resistance is the key mechanism of cancer escape from therapeutic attack and also the main obstacle for tumor therapy. Therefore, urgent exploration of the mechanisms of CRT resistance is required in order to improve therapeutic effects and reduce adverse reactions. Recent evidence suggests that lncRNAs may play vital roles in GC resistance to CRT (Figure 7B and Table 5).

LncRNA CRAL can regulate CYLD expression by binding to miR-505 and acting as an endogenous sponge, which can then reverse cisplatin resistance by increasing DNA damage and enhancing apoptosis. CYLD, a de-ubiquitinase, is considered a negative regulator of the PI3K/AKT/NF-κB signaling pathway. It was shown that in CRAL-deficient GC cells, CYLD expression was decreased and the activation of AKT increased. Blocking the PI3K/AKT signaling pathway reversed cisplatin resistance induced by CRAL deficiency and rendered GC cells sensitive to chemotherapeutic drugs. Thus, the suitability of AKT inhibitors for patients with GC could be determined based on the CRAL expression level. In summary, lncRNA CRAL may be a potential biomarker and therapeutic target for overcoming cisplatin resistance in GC by acting as a ceRNA via the miR-505/CYLD/AKT axis [188].

The autophagic adapter SQSTM1 (also known as the autophagic receptor) which recruits polyubiquitinated proteins to LC3-positive autophagosomes for degradation, can also recruit ARHGAP5-AS1 for autophagic degradation. However, in drug-resistant cancer cells with impaired autophagy, the amount of ARHGAP5-AS1 is upregulated and drug resistance increased. RBPs play an important role in regulating the stability of mRNA; it was also found that m^6^A modification can affect the stability of mRNA through RBPs such as HuR. ARHGAP5-AS1 modified ARHGAP5 mRNA by recruiting METTL3 for m^6^A modification and HuR binding, stimulated the transcription of ARHGAP5 in the nucleus, and also stabilized ARHGAP5 mRNA in the cytoplasm [189]. Therefore, targeting the ARHGAP5-AS1/ARHGAP5 axis may be a promising strategy for
overcoming chemoresistance in GC.

Abnormal expression of PCAT1, an important regulator of multidrug resistance, is found in many cancers. For example, upregulation of PCAT1 in esophageal cancer tissue reduces the sensitivity of cancer cells to cisplatin in vitro [190]. Functional studies on Caco-2 and HT-29 cells showed that silencing PCAT1 increased the sensitivity of the cells to 5-fluorouracil by upregulating the expression of c-Myc [191]. PCAT1 was also significantly upregulated in CDDP-resistant GC tissues and cells, and caused cisplatin resistance in GC cells by binding to EZH2 to increase H3K27me3, that silenced PTEN [150]. In conclusion, PCAT1 is a positive regulator of cisplatin resistance in cancer cells and targeting PCAT1 may be an effective drug resistance strategy.

To sum up, a variety of lncRNAs has been implicated as regulators of downstream gene expression and/or function via their action as ceRNAs or via directly acting on proteins, thereby regulating drug resistance. They can participate in the complex regulatory network of CRT by affecting the amplification or overexpression of oncogenes, suppression of tumor suppressor genes, immune escape, apoptosis, autophagy, EMT, programmed death, tumor stemness and potentially by other mechanisms as well. Targeting these maladjusted lncRNAs may be a promising strategy to reverse CRT-induced resistance. In addition, targeted treatment of GC with lncRNAs in combination with traditional chemotherapeutic agents may be a promising alternative to reversing drug resistance and may help improve the prognosis of patients with AGC. This approach may ultimately open up new potential avenues for overcoming therapy resistance.

Table 5. LncRNAs and the resistance to therapy

<table>
<thead>
<tr>
<th>Clinical application</th>
<th>LncRNA</th>
<th>Expression</th>
<th>Pathway</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>chemoradiotherapy</td>
<td>CRAL</td>
<td>down</td>
<td>miR-505/CYLD/AKT</td>
<td>[188]</td>
</tr>
</tbody>
</table>
Therapeutic strategies targeting specific IncRNAs

Regulatory IncRNA networks can mediate anti-proliferative effects and reduce invasion of GC, thus mediating therapeutic effects, and making it possible to consider exploiting IncRNAs as therapeutic targets in GC. One advantage of targeting IncRNAs is that functional ablation of a IncRNA with regulatory function may have pleiotropic effects, resulting in simultaneous damage to multiple tumor-related pathways. Therefore, targeting IncRNAs may yield reliable therapeutic results that reduce drug resistance in tumors. Small interference RNAs (siRNAs) targeting abnormal GC-specific IncRNAs may be an effective strategy in this respect [196]. Antisense oligonucleotides (ASOs) can also correct aberrant IncRNA networks by inducing RNase H-dependent degradation or by spatially blocking IncRNA activity. In addition, specific chemical modification of IncRNA-targeted ASOs enhances their effectiveness and stability and allows free absorption in vivo without the need for transfer methods [197]. In addition, the regulation of IncRNA expression based on CRISPR-Cas9 has been demonstrated as a therapeutic tool for clinical cancer therapy [198]. Although there is no clear evidence that this approach can be useful in GC, it is worth further exploring this avenue based on these theories. Finally, because IncRNAs are emerging new targets but with an as-yet incomplete understanding of their mechanisms of action, it is important to use controls in gene silencing studies to ensure that the observed phenotypes are caused by the interaction of the targets. In addition, some challenges, such as missed target effects, modes of targeted delivery, and activation of the immune response, need to be resolved before these IncRNAs can be considered for clinical application [199]. Although most studies to date on the use of IncRNA-targeted drugs for GC are still in the preclinical
phase, they nevertheless highlight the potential of this strategy (Figure 7C).

Conclusions and perspectives

In view of the high mortality and typically delayed diagnosis of gastric cancer (GC), a comprehensive understanding of the molecular pathogenesis and potential biomarkers of this disease is urgently needed to supplement existing treatment options. With the development of high throughput sequencing techniques such as microarrays or RNA-seq, important roles of various lncRNAs have been revealed. These have attracted the attention of investigators for their relevance also in the pathogenesis of GC. Large numbers of lncRNAs have been identified as being pertinent for pathology caused by imbalances in gene regulation and the resulting abnormalities in biological processes in GC, mainly due to the circumstantial evidence of their often-abnormal expression in GC.

In recent decades, studies have shown that lncRNAs regulate gene expression at transcriptional, post-transcriptional, and epigenetic levels, and participate in the occurrence, development, and progression of GC.

Screening of lncRNAs revealed that most of them have a promoting effect on GC, for example, Linc00152 and PANDA promote proliferation and growth and MAGI2-AS3 promotes tumor invasion and metastasis; however, only a few lncRNAs inhibit GC in vitro and in vivo, including PWRN1 and TUBA4B that inhibit the proliferation of GC cells. Irrespective of their promoting or inhibiting action on tumor growth, the characteristics of lncRNAs involved in the regulation of GC makes them theoretically potential biomarkers for GC diagnosis, prognosis, prediction and recurrence, some of which have also progressed to clinical trials. For example, PC antigen 3 (PCA3) detection test has been developed to assess prostate cancer risk using urine samples; this indicates progress and provides encouragement for further investigations [200]. Compared with traditional biomarkers, lncRNAs have the following advantages: (1) They have higher specificity and sensitivity. (2) LncRNAs testing is a simple, non-invasive, and easy-to-accept method. (3) LncRNAs can be used as biomarkers independently, in combination with other lncRNAs,
or as a consummate complement to classic cancer biomarkers. Moreover, because of the tissue- and disease-specific expression patterns of lncRNAs and their ability to control tumor micro-regulatory networks, they are of great significance not only as biomarkers but also as therapeutic targets. Thus, this is a promising field for molecular targeted therapy of GC. Strategies for targeting and regulating lncRNAs based on siRNAs, ASOs, CRISPR-Cas9, etc. are currently being explored, which will contribute to the development of more effective lncRNA-based GC treatment methods.

Moreover, some new types of lncRNAs have good prospects for applications and are worth exploring. Hitherto, some PROMPTs have been found to regulate cancer biology by interacting with adjacent proteins, and may also represent new biomarkers or therapeutic targets. Although there are few reports of PROMPTs specifically in the context of GC, they may provide new directions for future research on GC-related lncRNAs. Similar to PROMPTs, there is little data on eRNAs in GC, which may also gradually become a research hotspot.

Currently, there are numerous challenges for translating knowledge on lncRNAs to the clinic. First, their application must be based on knowledge of their mechanisms of action in vivo and in vitro, but only some of these have been well probed and elucidated. For example, how some lncRNAs affect DNA hydroxymethylation, chromatin remodeling, or alternative splicing of mRNAs in GC is still being explored. Owing to the complex nature of the tumor micro-environment and the involvement of multiple lncRNAs, we need to identify more lncRNAs affecting GC and construct a network of regulatory interactions between lncRNAs. Moreover, because lncRNAs function primarily through interactions with other biomolecules, elucidation of the secondary structure of their interaction domains is particularly necessary. The analysis of these lncRNA binding motifs may result in the identification of new RNA-based targets for disease prevention and treatment. At present, the study of lncRNAs in GC is mainly focused on their expression profiles, and the role of lncRNA mutants in gastric carcinogenesis needs further study. In addition, the low accessibility of lncRNAs is also a problem. Such problems can be tackled with the help of animal models and a new generation of technologies. The integration of functional
IncRNAs and GC biology will further our understanding of the mechanisms involved in GC carcinogenesis. Although the application of specific IncRNAs to diagnosis, prognosis, or treatment of GC is still a distant goal, there is no doubt about their significance. A comprehensive exploration of this still-mysterious realm will be expected to provide more new strategies for the prevention and treatment of GC in the near future.

**Abbreviations**

AGC: advanced GC; ASO: antisense oligonucleotide; ATG4B: autophagy-associated 4B; AUC: area under the curve; BTG2: B-cell translocation gene 2; CA: carbohydrate antigen; CCNE2: cyclin E2; CDK: cyclin-dependent kinase; CDK16: cyclin-dependent kinase 16; CEA: carcinoembryonic antigen; CRT: chemoradiotherapy; CSC: cancer stem cell; CXCL12: chemokine (CXCmotif) ligand; DDR: DNA damage response; DSP: desmoplakin; ECM: extracellular matrix; EGFR: epidermal growth factor receptor; EMT: epithelial-to-mesenchymal transition; eRNA: enhancer-associated RNA; FUS: fused in sarcoma; GC: gastric cancer; GEF: guanine exchange factor; GMAN: gastric cancer metastasis associated long noncoding RNA; GMAN-AS: antisense GMAN RNA; HDAC: histone deacetylase; hTERT: telomerase reverse transcriptase; H3K27me3: trimethylation of lysine residue 27 of histone 3; H3K4: histone H3 lysine K4; JAM-A: junctional adhesion molecule A; JMJD3: jumonji-domain containing 3; KLF: kruppel-like factor; KRT19P3: Keratin 19 Pseudogene 3; LIM-HD: LIM-homedomain; LMX1A: Lim homeobox transcription factor 1; IncRNA: long non-coding RNA; LOXL1-AS1: LOXL1 antisense RNA 1; MACC1: metastasis-associated in colon cancer-1; MACC1-AS1: MACC1 antisense RNA 1; MED18: mediator subunit 18; MMP: member matrix metalloproteinase; MNX1-AS1: MNX1 antisense RNA 1; MRE: miRNA response element; MSS: microsatellite stability; mTOR: rapamycin; m6A: N6-methyladenosine; ncRNA: non-coding RNA; NET1: neuroepithelial cell transforming gene 1; NFYA: nuclear transcription factor Y subunit alpha; NF-κB: nuclear factor kappa-B inhibitor; NORAD: The noncoding RNA activated by DNA damage; PANDAR: promoter of CDKN1A antisense DNA damage activated RNA; PCA3: PC antigen 3; PCD: programmed cell
Acknowledgements

We are grateful to Dr. Junjie Liu (UC Berkeley) and Prof. Yong Peng (Sichuan University) for their critical reviews on this manuscript. This work was supported in part by grants from National Science and Technology Major Project of the Ministry of Science and Technology of China (No. 2018ZX09735005), National Natural Science Foundation of China (Grant No. 81673455, Grant No. 81803365 and Grant No. 81873939), and Post-Doctorate Research Project (Grant No.2018M643510), Post-Doctorate Research Project of West China Hospital, Sichuan University (Grant No. 2018HXBH065).

Authors’ contributions

Y.C., Y.A., and B.L. conceived, extensively revised, formatted, and submitted the manuscript. H.T., S.Z., and J.Z. wrote the manuscript. L.Z., Y.C., and H.Y searched and archived the literature.

Competing interests

The authors declare that they have no conflict of interest.
Author details

1 State Key Laboratory of Biotherapy and Cancer Center, Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China. 2 College of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110064, China. 3 Department of Plastic Surgery, Peking University Third Hospital, Beijing 100191, China. 4 College of Stomatology, West China Hospital, Sichuan University, Chengdu 610041, China.

References


131. O’Connor MJ. Targeting the DNA Damage Response in Cancer. Mol Cell. 2015; 60: 547-60.


146. Cao S, Lin L, Xia X, Wu H. IncRNA SPRY4-IT1 Regulates Cell Proliferation and Migration by Sponging miR-101-3p and Regulating AMPK Expression in Gastric Cancer. Mol Ther Nucleic Acids. 2019; 17: 455-64.


164. Xiao Y, Pan J, Geng Q, Wang G. LncRNA MALAT1 increases the stemness of


